Biotech Values

[marthambles]

as an aside i think the assumption mL is worthless if tL wins approval seems like a prevasive mistake

Since the Lovenox generic sales would be pocket change to Teva, don't you think they would price tL sufficiently low to essentially deprive Momenta of any meaningful return, thereby exerting maximum financial pressure on the company that is threatening Teva's most important franchise?